Use of enhanced perinatal human immunodeficiency virus surveillance methods to assess antiretroviral use and perinatal human immunodeficiency virus transmission in the United States, 1999-2001

American Journal of Obstetrics and Gynecology

Volumn 197, Issue 3 SUPPL., 2007, Pages

  Harris, Norma S ^a   Fowler, Mary Glenn ^a   Sansom, Stephanie L ^a   Ruffo, Nan ^a,b   Lampe, Margaret A ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

antiretroviral; HIV AIDS; perinatal; surveillance

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; ZIDOVUDINE;

ADOLESCENT; ADULT; CONTROLLED STUDY; DISEASE TRANSMISSION; FEMALE; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; MAJOR CLINICAL STUDY; MONOTHERAPY; PERINATAL PERIOD; PRIORITY JOURNAL; REVIEW; RISK; UNITED STATES;

ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; DISEASE TRANSMISSION, VERTICAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; INFANT, NEWBORN; POPULATION SURVEILLANCE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROTEASE INHIBITORS; TREATMENT OUTCOME; UNITED STATES; ZIDOVUDINE;

EID: 34548384967     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2007.03.081     Document Type: Review

References (29)

1. Connor E.M., Sperling R.S., Gelber R., et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 331 (1994) 1173-1180
2. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States (revised November 3, 2000). HIV Clin Trials 2 (2001) 56-91
3. Centers for Disease Control and Prevention. Recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. MMWR Morb Mortal Wkly Rep 44 (1995) 1-14
4. Centers for Disease Control and Prevention. Revised recommendations for HIV screening of pregnant women. MMWR Morb Mortal Wkly Rep 50 (2001) 63-85
5. Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health care settings. MMWR Morb Mortal Wkly Rep 55 (2006) 1-16
6. Cooper E., Diaz C., Pitt J., et al. Impact of ACTG 076: use of ZDV (ZDV) during pregnancy and changes in the rate of HIV vertical transmission. Conf Retroviruses Opportunistic Infect 3 (1996) 57
7. Fiscus S.A., Adimora A.A., Schoenbach V.J., et al. Trends in human immunodeficiency virus (HIV) counseling, testing, and antiretroviral treatment of HIV-infected women and perinatal transmission in North Carolina. J Infect Dis 180 (1999) 99-105
8. Harris N.S., Thompson S.J., Ball R.T., Hussey J., and Sy F. Zidovudine and perinatal human immunodeficiency virus type 1 transmission: a population-based approach. Pediatrics 109 (2002) 1-7
9. Peters V., Liu K., Dominguez K., et al. Missed opportunities for perinatal HIV prevention among HIV-exposed infants born 1996-2000, pediatric spectrum of disease. Pediatrics 111 (2003) 1186-1191
10. Cooper E.R., Charurat M., Mofenson L., et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and the prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 29 (2004) 484-494
11. Mandelbrot L., Landreau-Mascaro A., Rekacewicz C., et al. Lamivudine-ZDV combination for prevention of maternal-infant transmission of HIV-1. JAMA 285 (2001) 2083-2093
12. Centers for Disease Control and Prevention. HIV/AIDS surveillance report (2001) 1-47 13
13. Fleming P.L., Lindegren M.L., Byers R.H., et al. Estimated number of perinatal HIV infections, United States, 2000. [abstract]. XIV International AIDS Conference (2002) Abstract TuPeC4773
14. Centers for Disease Control and Prevention. Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 48 (2004) 1-31
15. Centers for Disease Control and Prevention. HIV/AIDS surveillance report (2005) 1-46 15
16. Wade N.A., Zielinski M.A., Butsashvili M., et al. Decline in perinatal HIV transmission in New York State (1997-2000). J Acquir Immune Defic Syndr 36 (2004) 1075-1082
17. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. April 7. (2005). http://aidsinfo.nih.gov/guidelines/ Last accessed: July 25, 2005. Available at: http://aidsinfo.nih.gov/guidelines/.
18. Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States (2005) 1-16 February 24
19. Cooper E.R., Nugent R.P., Diaz C., et al. After AIDS clinical trial 076: the changing pattern of ZDV use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants: Women and Infants Transmission Study Group. J Infect Dis 174 (1996) 1207-1211
20. Fiscus S.A., Adimora A.A., Schoenbach V.J., et al. Perinatal HIV infection and the effect of ZDV therapy on transmission in rural and urban counties. JAMA 275 (1996) 1483-1488
21. Fiscus S.A., Adimora A.A., Funk M.L., et al. Trends in interventions to reduce perinatal human immunodeficiency virus type 1 transmission in North Carolina. Pediatr Infect Dis J 21 (2002) 664-668
22. Stiehm E.R., Lambert J.S., Mofenson L.M., et al. Efficacy of ZDV and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials group protocol 185. J Infect Dis 179 (1999) 567-575
23. Dorenbaum A., Cunningham C.K., Gelber R.D., et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA 288 (2002) 189-198
24. Lallemant M., Jourdain G., Le Coeur S., et al. A trial of shortened ZDV regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1: Perinatal HIV Prevention Trial (Thailand) investigators. N Engl J Med 343 (2000) 982-991
25. Lallemant M., Jourdain G., Le Coeur S., et al. Single-dose perinatal nevirapine plus standard ZDV to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 351 (2004) 217-228
26. Mandelbrot L., Le Chenadec J., Berrebi A., et al. Perinatal HIV-1 transmission: interaction between ZDV prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA 280 (1998) 55-60
27. Centers for Disease Control and Prevention. Advancing HIV prevention: new strategies for a changing epidemic: United States, 2003. MMWR Morb Mortal Wkly Rep 52 (2003) 329-332
28. Davis S.F., Byers Jr. R.H., Lindegren M.L., Caldwell M.B., Karon J.M., and Gwinn M. Prevalence and incidence of vertically acquired HIV infection in the United States. JAMA 274 (1995) 952-955
29. Wortley P.M., Lindegren M.L., and Fleming P.L. Successful implementation of perinatal HIV prevention guidelines: a multistate surveillance evaluation. MMWR Recomm Rep 50 (2001) 17-28